Alloy Therapeutics Stock
| Valuation | $1B1 |
| Valuation Date | Apr 15, 2026 |
| Implied Valuation | n/a |
| Last Price | $20.00 |
| 52-Week High | $20.00 |
| 52-Week Low | $20.00 |
| YTD Return | n/a |
| 1-Year Return | n/a |
| 3-Year Return | n/a |
| Total Funding | $176.24M2 |
| Latest Round Amount | $40M1 |
| Latest Round | Series E |
| Funding Rounds | 5 |
| IPO Status | Unknown |
| Expected IPO Date | n/a |
| Revenue | n/a |
| Revenue Type | n/a |
| P/S Ratio | n/a |
About Alloy Therapeutics
Alloy Therapeutics is a biotechnology company that sells drug discovery platforms and research services to other drug developers rather than running its own therapeutic pipeline. Its best known product is ATX-Gx, a suite of transgenic mouse strains used to find fully human antibodies, alongside newer offerings in bispecifics, TCR mimic antibodies, antisense genetic medicines, cell therapies and preclinical development. Alloy makes money by licensing these platforms for flat annual subscription fees with no milestones or royalties, and by running discovery and development programs for partners under service contracts. The company says more than 200 partners have used its technology, producing over 100 licensed therapeutic programs of which 22 have reached clinical development and two are in Phase 3.
Invest in Alloy Therapeutics
Alloy Therapeutics is a private company, so you can't purchase it with a regular brokerage account. However, its shares are available on Hiive.
Hiive is a secondary marketplace where accredited investors can buy and sell shares of private, pre-IPO companies. Invest in the world's most exciting startups before they go public.
Invest on HiiveStock Analysis may be compensated for user sign-ups through Hiive links. Hiive is not affiliated with Stock Analysis. Securities offered by Hiive Markets Limited, member of FINRA/SIPC.
Related Companies
News
Alloy is Building the World's First Fully Integrated Product Development Organization
Alloy set out its strategy to operate as a product development organization spanning discovery, preclinical and clinical development. The company frames the model as infrastructure that biotechs and p...
Voro Therapeutics and Alloy Therapeutics Enter Strategic Research Collaboration to Advance Next-Generation Masked T-Cell Engager Therapeutics
Alloy and San Diego based Voro Therapeutics agreed to work together on masked T-cell engager therapeutics. The collaboration pairs Voro's masking technology with Alloy's antibody discovery platforms.
Alloy Therapeutics and Institute for Protein Innovation Announce Strategic Collaboration to Advance Next-Generation Antibody Discovery
Alloy partnered with the Institute for Protein Innovation to create bespoke VHH nanobody libraries for next-generation bispecific and multispecific antibody discovery.
Alloy Therapeutics and Institute for Protein Innovation Announce Strategic Collaboration to Advance Next-Generation Antibody Discovery
Alloy entered a strategic collaboration with the nonprofit Institute for Protein Innovation on next-generation antibody discovery. The agreement expands the technologies Alloy can offer its discovery ...
Alloy Therapeutics Announces $40M Series E at $1 Billion Valuation
Alloy Therapeutics raised $40 million in a Series E round that values the company at $1 billion. The funding will expand its AI-driven discovery platforms, downstream development services, and global ...
Alloy Therapeutics Announces $40M Series E to Scale Tech-Enabled Biotech Infrastructure
Alloy raised a $40 million Series E round at a $1 billion valuation, led by investors including 8VC, JIC Venture Growth Investments and Echo Capital. The company said it would use the proceeds to expa...
Alloy Therapeutics Enters into Multi-Target Collaboration and License Agreement with Biogen for Use of Alloy's AntiClastic™ ASO Platform
BOSTON--(BUSINESS WIRE)--Alloy Therapeutics Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting-edge drug discovery technologies, today announced a collabora...
Alloy Therapeutics Appoints Alexander Titus to Lead New Vigilance Division
Alloy Therapeutics appointed Alexander Titus to lead a new Vigilance division focused on biosecurity and rapid therapeutic response. CEO Errik Anderson said the unit will strengthen Alloy's ability to...
Alloy Therapeutics Appoints Alexander Titus, Ph.D., to Lead New Vigilance Division Focused on Biosecurity and Rapid Therapeutic Response
Alloy created a Vigilance division focused on biosecurity and rapid therapeutic response and hired Alexander Titus to lead it. Titus previously held roles at ARPA-H and the US Department of Defense.
Alloy Therapeutics Enters Into Agreement to Advance Novel Antibody Discovery Platform
Alloy announced an agreement to develop a new antibody discovery platform. The deal adds to the transgenic mouse and screening technologies the company licenses to drug developers.
Alloy Accelerates Mediar Timeline to the Clinic for Complex Fibrosis Targets
Alloy described how its discovery services shortened Mediar Therapeutics' path to the clinic on difficult fibrosis targets. The case is an example of the venture-backed biotech clients Alloy is target...
Tahoe Therapeutics and Alloy Therapeutics to Form Joint Venture and Develop First-in-Class Antibody-Drug Conjugates for Hard-to-Treat Cancers
Alloy and Tahoe Therapeutics agreed to form a joint venture developing antibody-drug conjugates for hard-to-treat cancers. The structure is an example of Alloy's company-creation model.
Swiss Rockets Group and Alloy Therapeutics Partner to Advance Radioligand Therapeutics in Oncology
Alloy partnered with Switzerland's Swiss Rockets Group to advance radioligand therapeutics in oncology. The partnership extends Alloy's reach into a new therapeutic modality.
Alloy Therapeutics Appoints Christian Cobaugh, Ph.D., as CEO of Alloy Genetic Medicines
Alloy named Christian Cobaugh chief executive of its genetic medicines business. The unit commercializes the AntiClastic antisense oligonucleotide platform.
Alloy Therapeutics Announces Acquisition of Spannerwerks, a Leading Provider of Drug Development Consulting Services
Alloy acquired Spannerwerks, a Seattle drug development consulting firm, which now operates as a wholly owned subsidiary under its own name. Spannerwerks chief executive Dara Lockert joined Alloy's le...
Alloy Therapeutics and University of British Columbia Partner to Accelerate Antibody Discovery with Cryo-Electron Microscopy Technology
Alloy partnered with the University of British Columbia to apply cryo-electron microscopy to antibody discovery. The collaboration targets structural characterization of difficult antigens.
Alloy Therapeutics and Kansai Startup Academia Coalition (KSAC) Announce Strategic Collaboration to Accelerate Global Growth of Japanese Life Science Startups
Alloy agreed to work with the Kansai Startup Academia Coalition to support Japanese life science startups. The tie-up follows Alloy's move into Japan earlier in 2025.
Alloy Therapeutics Signs Memorandum of Understanding (MOU) with the Republic of Serbia to Support Global Bioeconomy Initiative
Alloy signed a memorandum of understanding with the Republic of Serbia to support a national bioeconomy initiative. The agreement is part of the company's push into sovereign and emerging innovation m...
Alloy Therapeutics enters Japanese market by establishing operations at Shonan Health Innovation Park
Alloy opened operations at Japan's Shonan Health Innovation Park, its first site in the country. The location focuses on cell therapy platform development and services.
Alloy Therapeutics Establishes Multi-Year Collaboration with Pfizer to Develop New Antibody Discovery Platform
BOSTON--(BUSINESS WIRE)--Alloy Therapeutics Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug discovery technologies, announced today its latest ...
Alloy Therapeutics Announces New Licensing Model for ATX-Gx Antibody Discovery Platform and Launches mAbForge High-Throughput Screening Service
Alloy introduced a new licensing model for its ATX-Gx transgenic mouse platform and launched mAbForge, a high-throughput antibody screening service. The changes are aimed at widening access for smalle...
Alloy Therapeutics Announces a Target Specific Collaboration and License Agreement for use of AntiClastic™ Antisense Platform with Sanofi
BOSTON--(BUSINESS WIRE)--Alloy Therapeutics Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug discovery technologies, announced today a target sp...
Alloy Therapeutics Signs Collaboration and License Agreement with Takeda to Develop Cell Therapy Platform
TOKYO & BOSTON--(BUSINESS WIRE)--Alloy Therapeutics Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug discovery technologies, announced today a s...
Alloy Therapeutics Announces Institutional License Agreement with Scripps Research for its ATX-Gx Platform for Fully Human Antibody Discovery
Scripps Research took an institutional license to Alloy's ATX-Gx fully human antibody discovery platform. The agreement gives researchers across the institute access to the transgenic mouse strains.
Alloy Therapeutics Announces Platform License Agreement with Lilly
BOSTON--(BUSINESS WIRE)--Alloy Therapeutics, a biotechnology ecosystem company dedicated to democratizing access to biologics drug discovery platforms and services, announced today a licensing agreeme...
Alloy Therapeutics to Empower Drug Discovery of Lundbeck's Biologics for Brain Health
BOSTON--(BUSINESS WIRE)--Alloy Therapeutics, a biotechnology ecosystem company, announced it is collaborating with Lundbeck, a global pharmaceutical company specializing in brain diseases, in the disc...
Champions Oncology Announces a Partnership with Alloy Therapeutics to Develop Therapeutic Monoclonal Antibodies for Use in ADC Programs
HACKENSACK, NJ / ACCESSWIRE / January 4, 2022 / Champions Oncology, Inc. (Nasdaq:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative pharmacology,...
Evotec Partners with Alloy Therapeutics to Expand its Antibody Discovery Platform
EVOTEC GAINS ACCESS TO ALLOY THERAPEUTICS' ATX-GX(TM) HUMANISED MICE PLATFORM FOR BIOLOGICS DISCOVERY PARTNERSHIP LEVERAGES COMPLEMENTARY STRENGTHS OF IN SILICO, IN VITRO AND IN VIVO ANTIBODY DISCOVER...